International Scientific Committee of Radionuclides in Nephrourology (ISCORN) Consensus on Renal Transit Time Measurements
This report is the conclusion of the international consensus committee on renal transit time (subcommittee of the International Scientific Committee of Radionuclides in Nephrourology) and provides recommendations on measurement, normal values, and analysis of clinical utility. Transit time is the time that a tracer remains within the kidney or within a part of the kidney (eg, parenchymal transit time). It can be obtained from a dynamic renogram and a vascular input acquired in standardized conditions by a deconvolution process. Alternatively to transit time measurement, simpler indices were proposed, such as time of maximum, normalized residual activity or renal output efficiency. Transit time has been mainly used in urinary obstruction, renal artery stenosis, or renovascular hypertension and renal transplant. Despite a large amount of published data on obstruction, only the value of normal transit is established. The value of delayed transit remains controversial, probably due to lack of a gold standard for obstruction. Transit time measurements are useful to diagnose renovascular hypertension, as are some of the simpler indices. The committee recommends further collaborative trials.
⁎Univ Paris-Sud, Department of Biophysics and Nuclear Medicine, Le Kremlin-Bicêtre, France.
†Department of Nuclear Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.
‡Department of Nuclear Medicine, St Bartholomew’s Hospital and Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London, United Kingdom.
§Department of Nuclear Medicine, Vejle Hospital, Vejle, Denmark.
¶Medical Physics Department, Pilgrim Hospital, Boston, Lincolnshire, United Kingdom.
∥Southampton University Hospitals NHS Trust, Southhampton, United Kingdom.
#Department of Nuclear Medicine, St Bartholomew’s Hospital, London, United Kingdom (retired).
⁎⁎Centre Hospitalo-Universitaire St Pierre, Brussels, Belgium.
††Department of Nuclear Medicine, Charles University Prague and the General Teaching Hospital, Prague, Czech Republic.
Address reprint requests to Emmanuel Durand, MD, PhD, Service de Biophysique et Médecine Nucléaire–CHU Bicêtre, 78 rue du Général Leclerc, F94275 Le Kremlin-Bicêtre, France.
Note: Throughout the text, the symbol “±” stands for standard deviation.
Conflicts of interest: K.E.B. was a consultant to Nuclear Diagnostics Ltd (Hermes work stations) from October 2004 to October 2005; he is no longer involved with this company.
The publication of this paper was made possible by a grant from ISCORN (A. Prigent) and contributions from A.T. Taylor and M.D. Blaufox.